Abstract:Abstract Introduction Key barriers restrict the utility (or use) of genetic information in making treatment decisions in metastatic PCa. First, the lack of platforms that link genomic and clinical outcome data limits our ability to uncover clinico-genomic associations. Second, predictions based on univariate biomarkers (e.g. individual mutations), are insufficient given the heterogeneity of metastatic genomes. Third, lack of predictive biomarkers for standard therapies limits the use of testing to prioritize patients for trials. We initiated CAPSTONE, a clinico-genomic resource and research study, to overcome these barriers. Methods CAPSTONE comprises three complementary discovery n=325, validation n=429, and real-world n=1,800 clinico-genomic cohorts, reflecting data characteristics in the research and real-world contexts. The discovery cohort includes PCa patients with RNA-seq and matched tumor germline exome sequencing (WES) from UM, the validation cohort has similar WES/RNA-seq data from non-UM mCRPC patients from the SU2C study. The real-world dataset is from PROMISE, a multi-institutional effort among 25+ PCa centers across the US utilizing commercial tests. Genetic and clinical data are harmonized through a uniform computational workflow and interoperable clinical data model. Results In this early report, we present results from the analysis of the discovery cohort with a median follow of 106 months (IQR, 90-121) and 91% PCa adenocarcinoma histology (n=292/325). 36 samples were from patients with localized disease, 101 from metastatic hormone sensitive PCa (mHSPC) and 191 from metastatic castrate resistant PCa (mCRPC). We called driver mutations, measured chromosomal instability (CIN), and obtained RNA-seq based readouts of pathway activity and immune infiltration. We were able to confirm all reported clinico-genomic associations in metastatic PCa, and identify multiple new ones. AR amplifications were found in 10% of mHSPC and were associated with significantly shorter survival on first-line therapy (p=0.0061). TP53 mutations were associated with worse OS from the time of biopsy on multivariable analysis (HR: 2.2; 1.7-2.9, p<0.001). OS from biopsy was worse for dual TP53/RB1 mutants when compared to TP53 or RB1 mutants alone, independent of the disease state at time of biopsy (HR, 4.3; 95% CI: 2.7-7.0, p<0.001). Surprisingly, both TP53 loss (p<0.001) and AR (p<0.001) amplification was associated with increased CIN (wGII). CIN increased in progression from localized to mHSPC to mCRPC (p=3e-5) and was independently associated with worse OS when controlled for covariates (HR: 3.28; 95% CI: 1.39-7.80, p=0.007). wGII-high tumors show upregulation of EMT-associated genes (q=6.8e-14), downregulation of AR-target genes (q=2.7e-6), and show lower CD8+ T cell levels (R=-0.24,p=7.7e-4). Conclusions We demonstrate the utility of CAPSTONE in identifying single-gene and complex genetic biomarkers associated with patient outcomes. Most notably, we identify CIN as one of the strongest independent genetic predictors of poor patient outcomes in PCa. Citation Format: Marcin Cieslik, Ryan Rebernick, Liat Hammer, Matt McFarlane, Thomas Westbrook, Yi-Mi Wu, Dan Robinson, Dan Spratt, Ajjai Alva, William Jackson, Zachery Reichert, Arul Chinnaiyan, Joshi Alumkal, Robert Dess. The carcinoma of prostate sequencing of tumor and clinical endpoints (CAPSTONE) project: A clinico-genomic resource to enable patient-centric genomic research and improve the actionability of genetic testing in metastatic prostate cancer [abstract]. In: Proceedings of the AACR Special Conference: Advances in Prostate Cancer Research; 2023 Mar 15-18; Denver, Colorado. Philadelphia (PA): AACR; Cancer Res 2023;83(11 Suppl):Abstract nr PR011.

A prospective study of comprehensive genomic testing to identify actionable variants in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms

Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study.

Characterizing longitudinal molecular changes in ctDNA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Circulating Tumor DNA-targeted Sequencing to Reveal Germline and Somatic Alterations That Can Guide Decision-Making in Metastatic Castration-Resistant Prostate Cancer.

Evaluation of ctDNA in patients with mCRPC with liver metastases.

Use of a navigable interface for integrated whole genome and transcriptome sequencing as a platform for pursuit of therapeutic targets in advanced prostate cancers.

Genomic amplifications identified by circulating tumor DNA analysis guide prognosis in metastatic castration-resistant prostate cancer

Homologous recombination repair gene mutation (HRRm) testing patterns and treatment selection from a real-world cohort of patients with metastatic castration-resistant prostate cancer (mCRPC).

Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study

Plasma cell-free DNA profiling of PI3K/Akt pathway aberrations in two multi-institutional independent metastatic castration-resistant prostate cancer (mCRPC) cohorts.

Abstract 3409: Whole genome sequencing of liquid tumor biopsies (ctDNA) from men with metastatic castration resistant prostate cancer

Complementary role for circulating tumor DNA and tumor tissue to detect clinical relevant alterations in patients with castrate-sensitive prostate cancer.

Safety and clinical validity of tumor genomic testing for guiding active surveillance selection in men with NCCN intermediate-risk prostate cancer.

Integrative Clinical Genomics of Advanced Prostate Cancer

Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing

Circulating Tumor DNA and RNA As an Exploratory Biomarker to Evaluate GT0918 in a Phase I/II Clinical Trial in Mcrpc Patients

Chromatin modifications on plasma ctDNA as a tool to phenotype castration-resistant prostate cancer.

Abstract PR011: The carcinoma of prostate sequencing of tumor and clinical endpoints (CAPSTONE) project: A clinico-genomic resource to enable patient-centric genomic research and improve the actionability of genetic testing in metastatic prostate cancer

Phenotypic differences related to homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) treated in routine care settings in the United States (US).

Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis